Insulet Corporation (NASDAQ:PODD) Stock Position Lifted by Cerity Partners LLC

Cerity Partners LLC lifted its holdings in Insulet Corporation (NASDAQ:PODD) by 28.7% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,232 shares of the medical instruments supplier’s stock after purchasing an additional 2,284 shares during the quarter. Cerity Partners LLC’s holdings in Insulet were worth $2,687,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of PODD. Itau Unibanco Holding S.A. bought a new position in Insulet during the fourth quarter valued at about $42,000. Golden State Wealth Management LLC boosted its stake in Insulet by 553.1% during the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier’s stock valued at $55,000 after buying an additional 177 shares in the last quarter. Coppell Advisory Solutions LLC boosted its stake in Insulet by 135.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier’s stock valued at $74,000 after buying an additional 162 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in Insulet by 23.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 59 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new position in Insulet during the fourth quarter valued at about $97,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Raymond James Financial reaffirmed an “outperform” rating and set a $360.00 target price (up from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Sanford C. Bernstein reissued an “outperform” rating on shares of Insulet in a research note on Friday, May 16th. Barclays raised their price objective on Insulet from $234.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 30th. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $350.00 price objective for the company in a research report on Tuesday, May 13th. Finally, Wells Fargo & Company set a $322.00 price objective on Insulet in a research report on Monday, April 28th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $321.00.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $284.23 on Friday. Insulet Corporation has a 1-year low of $173.00 and a 1-year high of $329.33. The firm has a market capitalization of $20.00 billion, a PE ratio of 51.12, a PEG ratio of 2.54 and a beta of 1.35. The business’s 50 day moving average is $309.07 and its 200-day moving average is $280.99. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating the consensus estimate of $0.81 by $0.21. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. Insulet’s quarterly revenue was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.73 EPS. Sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the business’s stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president owned 23,180 shares of the company’s stock, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.39% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.